References
- SequistLVYangJCYamamotoNPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331273327333423816960
- HidalgoMAmantFBiankinAVPatient-derived xenograft models: an emerging platform for translational cancer researchCancer Discov201449998101325185190
- SiegelRLMillerKDJemalACancer statistics, 2018CA Cancer J Clin201868173029313949
- TentlerJJTanACWeekesCDPatient-derived tumour xenografts as models for oncology drug developmentNat Rev Clin Oncol20129633835022508028
- DayCPMerlinoGvan DykeTPreclinical mouse cancer models: a maze of opportunities and challengesCell20151631395326406370
- FichtnerIRolffJSoongREstablishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkersClin Cancer Res200814206456646818927285
- JohnTKohlerDPintilieMThe ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancerClin Cancer Res201117113414121081655
- IlieMNunesMBlotLSetting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical stepsCancer Med20154220121125470237
- WangDPhamNATongJMolecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumorsInt J Cancer2017140366267327750381
- ZhangXCZhangJLiMEstablishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapiesJ Transl Med20131116823842453
- BankertRBEgilmezNKHessSDHuman-SCID mouse chimeric models for the evaluation of anti-cancer therapiesTrends Immunol200122738639311429323
- YamazakiSViciniPShenZPharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse modelsJ Pharmacol Exp Ther2012340354955722129595
- AndersonTMHessSDEgilmezNKNwoguCELenoxJMBankertRBComparison of human lung cancer/SCID mouse tumor xenografts and cell culture growth with patient clinical outcomesJ Cancer Res Clin Oncol20031291056556812923636
- GazdarAFSavageTKJohnsonJEThe comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lungJ Thorac Oncol201510455356425675280
- IzumiHYamasakiAUedaYSquamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma: a case report and literature reviewClin Lung Cancer2018191e63e6629126779
- LongoLMengoliMCBertoliniFBettelliSManfrediniSRossiGSynchronous occurrence of squamous-cell carcinoma “transformation” and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinomaLung Cancer2017103242628024692
- HouSZhouSQinZEvidence, mechanism, and clinical relevance of the transdifferentiation from lung adenocarcinoma to squamous cell carcinomaAm J Pathol2017187595496228284717
- LiuRWangXCurtissCMonoglyceride lipase gene knockout in mice leads to increased incidence of lung adenocarcinomaCell Death Dis2018923629348400
- MatrkaMCCimpermanKAHaasSRDek overexpression in murine epithelia increases overt esophageal squamous cell carcinoma incidencePLoS Genet2018143e100722729538372
- HowardSCHullSRHugginsJWCarrawayCACarrawayKLRelationship between xenotransplantability and cell surface properties of ascites sublines of a rat mammary adenocarcinomaJ Natl Cancer Inst198269133406954321
- ShoemakerRHThe NCI60 human tumour cell line anticancer drug screenNat Rev Cancer200661081382316990858